Zihao Tao, Yongkang Qiu, Zhao Chen, Wenpeng Huang, Lele Song, Aixiang Wang, Xuesong Li, Lei Kang
{"title":"Primary mesenchymal tumors of the prostate:<sup>18</sup>F FDG PET/CT findings.","authors":"Zihao Tao, Yongkang Qiu, Zhao Chen, Wenpeng Huang, Lele Song, Aixiang Wang, Xuesong Li, Lei Kang","doi":"10.1186/s13550-024-01177-4","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Primary mesenchymal tumors of the prostate are very rare, and there is no systematic report on fluorine-18-fluorodeoxyglucose positron emission tomography (<sup>18</sup>F-FDG PET/CT). The aim of this research was to characterize mesenchymal tumors of the prostate on <sup>18</sup>F-FDG PET/CT.</p><p><strong>Results: </strong>We included 13 patients with pathologically confirmed mesenchymal neoplasms of the prostate. The location, size, maximum standardized uptake value (SUVmax), metabolic tumor volume (MTV), total glycolysis of the lesion (TLG), pathologic findings, and available imaging study of the tumors were reviewed. Of the 13 patients (median age, 38 years; ranged from 13 to 74 years), the mean size of the tumors was 8.8 cm in diameter ranged from 5 to 16.1 cm. SUVmax ranged from 3.1 to 17.6 (mean 9.5), MTV ranged from 4.9 to 398 cm<sup>3</sup> (mean 109 cm<sup>3</sup>) and TLG ranged from 21.3 to 1216 g (mean 96 g). The seminal vesicles, rectum, and bladder are the most commonly affected sites of invasion, while metastasis typically occurs in the bones, lungs, and lymph nodes.</p><p><strong>Conclusions: </strong>Mesenchymal tumors of the prostate revealed large sizes and high SUVmax, MTV and TLG levels on <sup>18</sup>F-FDG PET/CT. <sup>18</sup>F-FDG PET/CT may be useful for accurate diagnosis, staging, and restaging, which plays an important role in the management of subsequent plans.</p>","PeriodicalId":11611,"journal":{"name":"EJNMMI Research","volume":"14 1","pages":"109"},"PeriodicalIF":3.1000,"publicationDate":"2024-11-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11564716/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"EJNMMI Research","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1186/s13550-024-01177-4","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING","Score":null,"Total":0}
引用次数: 0
Abstract
Background: Primary mesenchymal tumors of the prostate are very rare, and there is no systematic report on fluorine-18-fluorodeoxyglucose positron emission tomography (18F-FDG PET/CT). The aim of this research was to characterize mesenchymal tumors of the prostate on 18F-FDG PET/CT.
Results: We included 13 patients with pathologically confirmed mesenchymal neoplasms of the prostate. The location, size, maximum standardized uptake value (SUVmax), metabolic tumor volume (MTV), total glycolysis of the lesion (TLG), pathologic findings, and available imaging study of the tumors were reviewed. Of the 13 patients (median age, 38 years; ranged from 13 to 74 years), the mean size of the tumors was 8.8 cm in diameter ranged from 5 to 16.1 cm. SUVmax ranged from 3.1 to 17.6 (mean 9.5), MTV ranged from 4.9 to 398 cm3 (mean 109 cm3) and TLG ranged from 21.3 to 1216 g (mean 96 g). The seminal vesicles, rectum, and bladder are the most commonly affected sites of invasion, while metastasis typically occurs in the bones, lungs, and lymph nodes.
Conclusions: Mesenchymal tumors of the prostate revealed large sizes and high SUVmax, MTV and TLG levels on 18F-FDG PET/CT. 18F-FDG PET/CT may be useful for accurate diagnosis, staging, and restaging, which plays an important role in the management of subsequent plans.
EJNMMI ResearchRADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING&nb-
CiteScore
5.90
自引率
3.10%
发文量
72
审稿时长
13 weeks
期刊介绍:
EJNMMI Research publishes new basic, translational and clinical research in the field of nuclear medicine and molecular imaging. Regular features include original research articles, rapid communication of preliminary data on innovative research, interesting case reports, editorials, and letters to the editor. Educational articles on basic sciences, fundamental aspects and controversy related to pre-clinical and clinical research or ethical aspects of research are also welcome. Timely reviews provide updates on current applications, issues in imaging research and translational aspects of nuclear medicine and molecular imaging technologies.
The main emphasis is placed on the development of targeted imaging with radiopharmaceuticals within the broader context of molecular probes to enhance understanding and characterisation of the complex biological processes underlying disease and to develop, test and guide new treatment modalities, including radionuclide therapy.